查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1463137

化疗引起的中性粒细胞减少症治疗市场、占有率、规模、趋势、行业分析报告：依治疗、依分销管道、依地区

Chemotherapy Induced Neutropenia (CIN) Treatment Market Share, Size, Trends, Industry Analysis Report, by Treatment, Distribution Channel; By Region; Segment Forecast, 2024- 2032
出版日期: | 出版商: Polaris Market Research | 英文 114 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的最新研究，预计到 2032 年，全球化疗引起的中性粒细胞减少症治疗市场规模将达到 7.7584 亿美元。 该研究报告提供了对当前市场动态的详细见解，并对未来市场成长进行了分析。

全球癌症发生率的增加是化疗引起的中性粒细胞减少症 (CIN) 治疗市场的关键驱动因素。 癌症发生率上升的主要原因是人口快速老化。 由于基因突变、免疫系统减弱、长期接触致癌物质、DNA修復机制受损、荷尔蒙波动以及与年龄相关的慢性疾病等多种因素，老龄化人群更容易患癌症。

不健康的生活习惯，例如吸烟、久坐习惯、不良饮食习惯和过量饮酒，进一步导致全球癌症发生率上升。 癌症仍然是世界上最主要的死亡原因，光在 2020 年就夺走了约 1,000 万人的生命，几乎占死亡人数的六分之一。 最常见的癌症类型是乳癌（226万人）、肺癌（221万人）、大肠癌（193万人）、摄护腺癌（141万人）和皮肤癌（120万人）。人）。 此外，每年约有 40 万名儿童被诊断出罹患癌症。

化疗引起的中性粒细胞减少症 (CIN) 通常是化疗的副作用，它会减少中性粒细胞的数量，中性粒细胞是对抗感染所必需的一种白血球。 化疗药物会干扰骨髓产生嗜中性球的能力，削弱免疫系统并增加感染的可能性。 CIN 常导致治疗延迟和化疗剂量减少，影响治疗效果。

经历 CIN 的患者发生严重感染并需要住院治疗的风险增加。 因此，仔细监测和适当管理化疗引起的中性粒细胞减少症对于最大限度地减少併发症和优化癌症治疗至关重要。 这凸显了对有效解决 CIN 的客製化治疗方法的需求不断增长。

全球癌症发生率的上升导致接受化疗的患者人数增加，从而导致对化疗引起的中性粒细胞减少症 (CIN) 的有效治疗的需求增加。 需求激增预计将成为市场成长的主要催化剂。 此外，化疗方案的进步，包括引入更有效的标靶疗法，正在提高癌症治疗的有效性。 然而，这些发展也增加了 CIN 的风险。 因此，迫切需要製定改进的策略来预防和管理化疗患者中性粒细胞减少症。

化疗引起的中性粒细胞减少症治疗市场报告亮点

G-CSF製剂作为黄金标准治疗药物获得最大占有率

医院药局凭藉完善的设备和外科医生占市场主导地位

由于癌症患者数量的增加和化疗的使用，亚太地区预计将录得强劲增长率

主要市场参与者包括艾伯维 (AbbVie)、Coherus BioSciences、葛兰素史克 (GlaxoSmithKline)、Lupin、G1 Therapeutics、默克 (Merck)、诺华 (Novartis) 和 Spectrum Pharmaceuticals。

目录

第一章简介

第 2 章执行摘要

第三章研究方法

第 4 章全球化疗引起的中性粒细胞减少症 (CIN) 治疗市场洞察

  • 化疗引起的中性粒细胞减少症 (CIN) 治疗市场 - 产业快照
  • 化疗引起的中性粒细胞减少症 (CIN) 治疗市场动态
    • 推动者和机会
      • 癌症患者数量不断增加，并且越来越多地使用化疗作为治疗选择
      • 化疗引起嗜中性白血球减少症的可能性增加
    • 抑制因素和课题
      • 治疗费用飙涨和监管政策严格
  • 杵分析
  • 化疗引起的中性粒细胞减少症 (CIN) 治疗行业的趋势
  • 价值链分析
  • 新冠肺炎 (COVID-19) 影响分析

第 5 章化疗引起的中性粒细胞减少症 (CIN) 治疗的全球市场（依治疗类型划分）

  • 主要发现
  • 简介
  • 抗生素治疗
  • 粒细胞集落刺激因子疗法 (G-CSF)
  • 粒细胞输注
  • 其他

第 6 章全球化疗引起的中性粒细胞减少症 (CIN) 治疗市场（依分销管道）

  • 主要发现
  • 简介
  • 医院药房
  • 零售药局
  • 网路药局

第 7 章全球化疗引起的中性粒细胞减少症 (CIN) 治疗市场（依地区）

  • 主要发现
  • 简介
    • 2019-2032 年化疗引起的中性粒细胞减少症 (CIN) 治疗市场评估（依地区）
  • 化疗引起的中性粒细胞减少症 (CIN) 治疗市场 - 北美
    • 北美：化疗引起的中性粒细胞减少症 (CIN) 治疗市场，依分销管道划分，2019-2032 年
    • 北美：化疗引起的中性粒细胞减少症 (CIN) 治疗市场（依治疗类型），2019-2032 年
    • 化疗引起的中性粒细胞减少症 (CIN) 治疗市场 - 美国
    • 化疗引起的中性粒细胞减少症 (CIN) 治疗市场 - 加拿大
  • 化疗引起的中性粒细胞减少症 (CIN) 治疗市场 - 欧洲
    • 欧洲：化疗引起的中性粒细胞减少症 (CIN) 治疗市场（依分销管道），2019-2032 年
    • 欧洲：2019-2032 年化疗引起的中性粒细胞减少症 (CIN) 治疗市场（依治疗类型）
    • 化疗引起的中性粒细胞减少症 (CIN) 治疗市场 - 英国
    • 化疗引起的中性粒细胞减少症 (CIN) 治疗市场 - 法国
    • 化疗引起的中性粒细胞减少症 (CIN) 治疗市场 - 德国
    • 化疗引起的中性粒细胞减少症 (CIN) 治疗市场 - 义大利
    • 化疗引起的中性粒细胞减少症 (CIN) 治疗市场 - 西班牙
    • 化疗引起的中性粒细胞减少症 (CIN) 治疗市场 - 荷兰
    • 化疗引起的中性粒细胞减少症 (CIN) 治疗市场 - 俄罗斯
  • 化疗引起的中性粒细胞减少症 (CIN) 治疗市场 - 亚太地区
    • 亚太地区：化疗引起的中性粒细胞减少症 (CIN) 治疗市场（依分销管道），2019-2032 年
    • 亚太地区：2019-2032 年化疗引起的中性粒细胞减少症 (CIN) 治疗市场（依治疗类型）
    • 化疗引起的中性粒细胞减少症 (CIN) 治疗市场 - 中国
    • 化疗引起的中性粒细胞减少症 (CIN) 治疗市场 - 印度
    • 化疗引起的中性粒细胞减少症 (CIN) 治疗市场 - 马来西亚
    • 化疗引起的中性粒细胞减少症 (CIN) 治疗市场 - 日本
    • 化疗引起的中性粒细胞减少症 (CIN) 治疗市场 - 印度尼西亚
    • 化疗引起的中性粒细胞减少症 (CIN) 治疗市场 - 韩国
  • 化疗引起的中性粒细胞减少症 (CIN) 治疗市场 - 中东和非洲
    • 中东和非洲：化疗引起的中性粒细胞减少症 (CIN) 治疗市场（依分销管道），2019-2032 年
    • 中东和非洲：2019-2032 年化疗引起的中性粒细胞减少症 (CIN) 治疗市场（依治疗类型）
    • 化疗引起的中性粒细胞减少症 (CIN) 治疗市场 - 沙乌地阿拉伯
    • 化疗引起的中性粒细胞减少症 (CIN) 治疗市场 - 阿联酋
    • 化疗引起的中性粒细胞减少症 (CIN) 治疗市场 - 以色列
    • 化疗引起的中性粒细胞减少症 (CIN) 治疗市场 - 南非
  • 化疗引起的中性粒细胞减少症 (CIN) 治疗市场 - 拉丁美洲
    • 拉丁美洲：化疗引起的中性粒细胞减少症 (CIN) 治疗市场（依分销管道），2019-2032 年
    • 拉丁美洲：2019-2032 年化疗引起的中性粒细胞减少症 (CIN) 治疗市场（依治疗类型）
    • 化疗引起的中性粒细胞减少症 (CIN) 治疗市场 - 墨西哥
    • 化疗引起的中性粒细胞减少症 (CIN) 治疗市场 - 巴西
    • 化疗引起的中性粒细胞减少症 (CIN) 治疗市场 - 阿根廷

第八章竞争态势

  • 扩张与收购分析
    • 放大
    • 收购
  • 合作/协作/合约/展览

第九章公司简介

  • AbbVie Inc.（Allergan PLC）
  • Aurobindo Pharma
  • Coherus BioSciences
  • GlaxoSmithKline PLC.
  • Lupin, G1 Therapeutics, Inc
  • Merck & Co., Inc
  • Novartis AG
  • Spectrum Pharmaceuticals
Product Code: PM4799

The global chemotherapy induced neutropenia treatment market size is expected to reach USD 775.84 million by 2032, according to a new study by Polaris Market Research. The report "Chemotherapy Induced Neutropenia (CIN) Treatment Market Share, Size, Trends, Industry Analysis Report, by Treatment (Antibiotic Therapy, Granulocyte Colony-Stimulating Factor Therapy, Granulocyte Transfusion, and Others), Distribution Channel; By Region; Segment Forecast, 2024- 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The increasing global incidence of cancer serves as a significant driver for the chemotherapy-induced neutropenia (CIN) treatment market. A major contributing factor to the rising cancer rates is the rapidly expanding aging population. The aging demographic is more susceptible to cancer due to various factors such as genetic mutations, weakened immune systems, prolonged exposure to carcinogens, impaired DNA repair mechanisms, hormonal fluctuations, and age-related chronic ailments.

Unhealthy lifestyle behaviours, including tobacco consumption, sedentary habits, poor dietary choices, and excessive alcohol intake, further contribute to the escalating cancer incidence worldwide. Cancer remains a leading cause of death globally, claiming nearly 10 Mn lives in 2020 alone, which accounts for nearly one in six deaths. The most prevalent cancer types include breast cancer (2.26 Mn cases), lung cancer (2.21 Mn), colon and rectal cancer (1.93 Mn cases), prostate cancer (1.41 Mn), skin cancer (1.20 Mn), and stomach cancer (1.09 Mn). Additionally, approximately 400,000 children are diagnosed with cancer annually.

Chemotherapy-induced neutropenia (CIN) commonly occurs as a side effect of chemotherapy, wherein the number of neutrophils, a type of white blood cell vital for combating infections, decreases. Chemotherapy medications hinder the bone marrow's ability to generate neutrophils, weakening the immune system and heightening vulnerability to infections. CIN often leads to treatment delays or reductions in chemotherapy dosage, impacting treatment effectiveness.

Patients experiencing CIN face a heightened risk of developing severe infections, necessitating hospitalization. Consequently, careful monitoring and appropriate management of chemotherapy-induced neutropenia are essential to minimize complications and optimize cancer treatment delivery. This underscores the increasing demand for tailored treatment approaches to address CIN effectively.

The rising global cancer rates have necessitated a larger cohort of patients undergoing chemotherapy, consequently escalating the demand for efficient management of chemotherapy-induced neutropenia (CIN). This surge in demand is anticipated to serve as a primary catalyst for the growth of the market. Furthermore, advancements in chemotherapy protocols, including the introduction of more potent and targeted therapies, have enhanced cancer treatment efficacy. However, these developments have concurrently heightened the risk of CIN. Consequently, there is an increased urgency to develop improved strategies for the prevention and management of neutropenia in chemotherapy patients.

Chemotherapy Induced Neutropenia Treatment Market Report Highlights

G-CSF segment garnered the largest share, as it is considered as gold standard treatment option

Hospital pharmacies dominated the market, as they are fully equipped with the facilities and surgeons

APAC expected to register robust growth rate, owing to the rise in cancer cases and use of chemotherapy

The key market players include AbbVie, Coherus BioSciences, GlaxoSmithKline, Lupin, G1 Therapeutics, Merck, Novartis, and Spectrum Pharmaceuticals

Polaris Market Research has segmented the chemotherapy induced neutropenia treatment market report based on treatment type, distribution channel, and region:

Chemotherapy Induced Neutropenia Treatment Market, Type Outlook (Revenue - USD Million, 2023 - 2032)

  • Antibiotic Therapy
  • Granulocyte Colony-Stimulating Factor Therapy (G-CSF)
  • Granulocyte Transfusion
  • Others

Chemotherapy Induced Neutropenia Treatment Market, Distribution Channel Outlook (Revenue - USD Million, 2023 - 2032)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Chemotherapy Induced Neutropenia Treatment Market, Regional Outlook (Revenue - USD Million, 2023 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market Insights

  • 4.1. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Industry Snapshot
  • 4.2. Chemotherapy Induced Neutropenia (CIN) Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising cases of cancer and increasing use of chemotherapy as treatment option
      • 4.2.1.2. Rising likelihood of chemotherapy induced neutropenia
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost of treatment and stringent regulatory policies
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Chemotherapy Induced Neutropenia (CIN) Treatment Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Chemotherapy Induced Neutropenia (CIN) Treatment, by Treatment Type, 2019-2032 (USD Million)
  • 5.3. Antibiotic Therapy
    • 5.3.1. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Antibiotic Therapy, by Region, 2019-2032 (USD Million)
  • 5.4. Granulocyte Colony-Stimulating Factor Therapy (G-CSF)
    • 5.4.1. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Granulocyte Colony-Stimulating Factor Therapy (G-CSF), by Region, 2019-2032 (USD Million)
  • 5.5. Granulocyte Transfusion
    • 5.5.1. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Granulocyte Transfusion, by Region, 2019-2032 (USD Million)
  • 5.6. Others
    • 5.6.1. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Others, by Region, 2019-2032 (USD Million)

6. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Hospital Pharmacies, by Region, 2019-2032 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Retail Pharmacies, by Region, 2019-2032 (USD Million)
  • 6.5. Online Pharmacies
    • 6.5.1. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Online Pharmacies, by Region, 2019-2032 (USD Million)

7. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Chemotherapy Induced Neutropenia (CIN) Treatment Market Assessment, By Geography, 2019-2032 (USD Million)
  • 7.3. Chemotherapy Induced Neutropenia (CIN) Treatment Market - North America
    • 7.3.1. North America: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.3.2. North America: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.3.3. Chemotherapy Induced Neutropenia (CIN) Treatment Market - U.S.
      • 7.3.3.1. U.S.: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.3.3.2. U.S.: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.3.4. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Canada
      • 7.3.4.1. Canada: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.3.4.2. Canada: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • 7.4. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Europe
    • 7.4.1. Europe: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.4.2. Europe: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.4.3. Chemotherapy Induced Neutropenia (CIN) Treatment Market - UK
      • 7.4.3.1. UK: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.4.3.2. UK: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.4.4. Chemotherapy Induced Neutropenia (CIN) Treatment Market - France
      • 7.4.4.1. France: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.4.4.2. France: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.4.5. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Germany
      • 7.4.5.1. Germany: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.4.5.2. Germany: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.4.6. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Italy
      • 7.4.6.1. Italy: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.4.6.2. Italy: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.4.7. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Spain
      • 7.4.7.1. Spain: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.4.7.2. Spain: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.4.8. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Netherlands
      • 7.4.8.1. Netherlands: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.4.8.2. Netherlands: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.4.9. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Russia
      • 7.4.9.1. Russia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.4.9.2. Russia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • 7.5. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Asia Pacific
    • 7.5.1. Asia Pacific: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.5.2. Asia Pacific: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.5.3. Chemotherapy Induced Neutropenia (CIN) Treatment Market - China
      • 7.5.3.1. China: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.5.3.2. China: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.5.4. Chemotherapy Induced Neutropenia (CIN) Treatment Market - India
      • 7.5.4.1. India: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.5.4.2. India: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.5.5. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Malaysia
      • 7.5.5.1. Malaysia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.5.5.2. Malaysia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.5.6. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Japan
      • 7.5.6.1. Japan: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.5.6.2. Japan: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.5.7. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Indonesia
      • 7.5.7.1. Indonesia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.5.7.2. Indonesia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.5.8. Chemotherapy Induced Neutropenia (CIN) Treatment Market - South Korea
      • 7.5.8.1. South Korea: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.5.8.2. South Korea: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • 7.6. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.6.2. Middle East & Africa: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.6.3. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.6.3.2. Saudi Arabia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.6.4. Chemotherapy Induced Neutropenia (CIN) Treatment Market - UAE
      • 7.6.4.1. UAE: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.6.4.2. UAE: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.6.5. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Israel
      • 7.6.5.1. Israel: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.6.5.2. Israel: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.6.6. Chemotherapy Induced Neutropenia (CIN) Treatment Market - South Africa
      • 7.6.6.1. South Africa: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.6.6.2. South Africa: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • 7.7. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Latin America
    • 7.7.1. Latin America: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.7.2. Latin America: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.7.3. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Mexico
      • 7.7.3.1. Mexico: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.7.3.2. Mexico: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.7.4. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Brazil
      • 7.7.4.1. Brazil: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.7.4.2. Brazil: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.7.5. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Argentina
      • 7.7.5.1. Argentina: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.7.5.2. Argentina: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. AbbVie Inc. (Allergan PLC)
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Aurobindo Pharma
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Coherus BioSciences
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. GlaxoSmithKline PLC.
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Lupin, G1 Therapeutics, Inc
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Merck & Co., Inc
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Novartis AG
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Spectrum Pharmaceuticals
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development

List of Tables

  • Table 1 Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 2 Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 3 Chemotherapy Induced Neutropenia (CIN) Treatment Market Assessment, By Geography, 2019-2032 (USD Million)
  • Table 4 North America: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 5 North America: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 6 U.S.: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 7 U.S.: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 8 Canada: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 9 Canada: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 10 Europe: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 11 Europe: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 12 UK: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 13 UK: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 14 France: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 15 France: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 16 Germany: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 17 Germany: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 18 Italy: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 19 Italy: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 20 Spain: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 21 Spain: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 22 Netherlands: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 23 Netherlands: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 24 Russia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 25 Russia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 26 Asia Pacific: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 27 Asia Pacific: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 28 China: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 29 China: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 30 India: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 31 India: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 32 Malaysia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 33 Malaysia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 34 Japan: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 35 Japan: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 36 Indonesia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 37 Indonesia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 38 South Korea: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 39 South Korea: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 40 Middle East & Africa: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 41 Middle East & Africa: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 42 Saudi Arabia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 43 Saudi Arabia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 44 UAE: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 45 UAE: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 46 Israel: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 47 Israel: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 48 South Africa: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 49 South Africa: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 50 Latin America: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 51 Latin America: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 52 Mexico: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 53 Mexico: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 54 Brazil: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 55 Brazil: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 56 Argentina: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 57 Argentina: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)

List of Figures

  • Figure 1 Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, 2019-2032 (USD Million)
  • Figure 2 Integrated Ecosystem
  • Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4 Market by Geography
  • Figure 5 Porter's Five Forces
  • Figure 6 Market by Distribution Channel
  • Figure 7 Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2022 & 2032 (USD Million)
  • Figure 8 Market by Treatment Type
  • Figure 9 Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2022 & 2032 (USD Million)
  • Figure 10 Chemotherapy Induced Neutropenia (CIN) Treatment Market Assessment, By Geography, 2019-2032 (USD Million)
  • Figure 11 Strategic Analysis - Chemotherapy Induced Neutropenia (CIN) Treatment Market